Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Radient Pharmaceuticals (RPC) and its wholly-owned subsidiary NuVax Therapeutics have entered into an agreement with the University of Florida College of Medicine in Gainesville for the use and commercialization of four patented immune-gene therapy tools and systems developed by Lung-Ji Chang, professor of Molecular Genetics and Microbiology at University of Florida's Research Center.
Subscribe to our email newsletter
The new tools and systems are anticipated to allow NuVax to develop three separate cancer therapeutics for the treatment of Multi Myeloma, Pancreatic Cancer and Lung Cancer.
As per the terms of the agreement, NuVax intends to leverage the four newly licensed tools and systems for selective targeting of patient tumor cells to invoke a stronger immune response in cancer patients.
RPC chairman and CEO Douglas MacLellan said they plan to leverage their experience and expertise in product development, manufacturing, regulatory approvals, and sales and marketing to fully commercialize these new therapies and technologies as rapidly as possible.